Nucleome Therapeutics builds a cell-platform that creates 3D genome structure maps and enables variant functional validation at scale in primary cell types. The company links disease-linked genetic variants to gene function to precisely map disease pathways, with an initial focus on lymphocytes and related autoimmune diseases. Nucleome aims to build a pipeline of drug assets alongside corresponding biomarkers. Led by CEO Dr Danuta Jeziorska, the company intends to use new funding to advance its autoimmune disease programs and further develop its platform. The firm also plans to accelerate expansion of its dark genome atlas to unlock the therapeutic value of noncoding variants. Financially, the company announced a £37.5M Series A in October 2022.

Total raised

$42M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2022